Gilead Sciences (NASDAQ:GILD) Price Target Raised to $123.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by Royal Bank Of Canada from $120.00 to $123.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Citigroup lifted their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Wednesday. Barclays cut their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday. Finally, Truist Financial dropped their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $133.21 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.14 and a quick ratio of 1.77. The company has a market cap of $165.39 billion, a price-to-earnings ratio of -49.89 and a beta of 0.32. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29. The stock’s 50 day simple moving average is $129.41 and its two-hundred day simple moving average is $136.20.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 earnings per share. As a group, equities analysts anticipate that Gilead Sciences will post -0.49 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 82,000 shares of company stock valued at $10,641,790. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the fourth quarter worth $25,000. Persistent Asset Partners Ltd purchased a new stake in Gilead Sciences in the second quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $26,000. Finally, Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead raised its 2026 base-business outlook, citing continued strength in its HIV portfolio and growing PrEP demand. Management also highlighted Trodelvy growth and two potential product launches in the second half of the year. GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
• Positive Sentiment: Second-quarter revenue of $7.80 billion exceeded expectations, and revenue increased 10.6% year over year. Although reported earnings were distorted by acquisition-related items, the underlying operating performance was viewed as stronger than the headline loss suggests. Gilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss
• Positive Sentiment: Analysts at Cantor Fitzgerald and Needham & Company reiterated favorable views, assigning Gilead Overweight and Buy ratings, respectively. Gilead Sciences Earns Overweight Rating from Cantor Fitzgerald Gilead Sciences Earns Buy Rating from Needham
• Neutral Sentiment: Gilead’s research pipeline could provide longer-term growth, but investors are weighing whether development spending and potential launches can translate into sustainable commercial returns. Can Gilead Sciences Turn Research Into Growth?
• Neutral Sentiment: RBC raised its Gilead price target to $123, signaling a more constructive view, though the target remains below the reference market price and therefore offers limited near-term upside. RBC Increases Gilead Sciences Price Target
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lackluster interim data, weakening expectations for a major combination-therapy expansion of Trodelvy. MSD and Gilead scrap Phase III Trodelvy-Keytruda study

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.